文献速递免疫规划传染病防控与疫情报告

2022-23年度季节性流感疫苗效果的临时估计——威斯康星州,2022年10月至2023年2月

Interim Estimates of 2022-23 Seasonal Influenza Vaccine Effectiveness - Wisconsin, October 2022-February 2023.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2023-02-24

2022-23年度流感季早期,美国威斯康星州Marshfield Clinic Health System开展的两项同期研究评估了流感疫苗效果。在6月龄至64岁人群中,疫苗对实验室确诊甲型流感相关的门诊急性呼吸道疾病的有效性为54%;在18岁以下儿童和青少年社区队列中,疫苗对有症状实验室确诊甲型流感病毒感染的有效性为71%。

要点

  • 6月龄至64岁人群流感疫苗对门诊甲型流感相关急性呼吸道疾病有效性为54%。
  • 18岁以下儿童和青少年中流感疫苗对有症状实验室确诊甲型流感病毒感染有效性为71%。
  • CDC建议≥6月龄人群在流感病毒流行期间继续接种年度流感疫苗。

核心结论

  • 临时分析表明流感疫苗接种大幅降低了65岁以下人群门诊流感风险和儿童青少年症状性流感风险。
  • 年度流感疫苗接种是预防流感及其并发症的最佳策略。

研究设计与样本

  • 使用2022年10月23日至2023年2月10日在威斯康星州Marshfield Clinic Health System开展的两项同期研究的数据估计流感疫苗有效性。
  • 一项为6月龄至64岁患者中评估疫苗对门诊急性呼吸道疾病的有效性,另一项为18岁以下儿童和青少年社区队列。

主要发现

  • 总体疫苗有效性为54%,针对6月龄至64岁患者中实验室确诊甲型流感相关的门诊急性呼吸道疾病。
  • 在18岁以下儿童和青少年社区队列中,疫苗有效性为71%,针对有症状实验室确诊甲型流感病毒感染。
  • 2022-23年度流感活动较往常开始更早,2022年10月增加,并与儿童高住院率相关。
  • 检测和分型的流感病毒以甲型H3N2为主,甲型H1N1pdm09也共同循环。
  • 大多数特征性病毒与2022-23年度北半球流感疫苗所含病毒属于同一遗传亚分支且抗原性相似。

关键数值与推荐

  • 疫苗有效性因季节、流感病毒亚型和与循环病毒的抗原匹配而异。
  • CDC建议医疗提供者在流感病毒流行期间继续为≥6月龄人群接种年度流感疫苗。

临床怎么用

  • CDC建议医疗提供者在流感病毒流行期间继续为≥6月龄人群接种年度流感疫苗。
  • 年度流感疫苗接种是预防流感及其并发症的最佳策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the United States, 2022-23 influenza activity began earlier than usual, increasing in October 2022, and has been associated with high rates of hospitalizations among children* (1). Influenza A(H3N2) represented most influenza viruses detected and subtyped during this period, but A(H1N1)pdm09 viruses cocirculated as well. Most viruses characterized were in the same genetic subclade as and antigenically similar to the viruses included in the 2022-23 Northern Hemisphere influenza vaccine (1,2). Effectiveness of influenza vaccine varies by season, influenza virus subtype, and antigenic match with circulating viruses. This interim report used data from two concurrent studies conducted at Marshfield Clinic Health System (MCHS) in Wisconsin during October 23, 2022-February 10, 2023, to estimate influenza vaccine effectiveness (VE). Overall, VE was 54% against medically attended outpatient acute respiratory illness (ARI) associated with laboratory-confirmed influenza A among patients aged 6 months-64 years. In a community cohort of children and adolescents aged <18 years, VE was 71% against symptomatic laboratory-confirmed influenza A virus infection. These interim analyses indicate that influenza vaccination substantially reduced the risk for medically attended influenza among persons aged <65 years and for symptomatic influenza in children and adolescents. Annual influenza vaccination is the best strategy for preventing influenza and its complications. CDC recommends that health care providers continue to administer annual influenza vaccine to persons aged ≥6 months as long as influenza viruses are circulating (2).

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. McLean HQ, Petrie JG, Hanson KE, et al. Interim Estimates of 2022-23 Seasonal Influenza Vaccine Effectiveness - Wisconsin, October 2022-February 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36821715. doi:10.15585/mmwr.mm7208a1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。